- Monday, June 24, 2024 @ 8:00 am
Ymmunobio and EVIIVE are pleased to announce their strategic collaboration to develop an innovative liquid biopsy technology utilizing extracellular vesicles (EVs). This partnership marks a significant advancement in precision medicine, aiming to enhance disease detection and patient monitoring accuracy and efficacy.
The newly developed liquid biopsy will utilize the unique properties of EVs to provide a non-invasive and highly precise diagnostic tool. Ymmunobio plans to leverage this cutting-edge technology to test patients for NPTXR. This will help determine their eligibility for treatment with their YB-800 platform drugs, ensuring more personalized and effective treatment strategies.
Dr. Peter Schiemann, Ymmunobio CEO and Chair of the Board says: “This collaboration with EVIIVE underscores both companies’ commitment to innovation and improving patient outcomes through advanced diagnostic and therapeutic solutions. We are proud to have found a great partner with such an innovative diagnostic solution. Together, Ymmunobio and EVIIVE are pioneering advances in diagnostics and oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients.”
Dr. Kevin Yim, EVIIVE Co-founder and CEO says: "We are excited to collaborate with Ymmunobio to co-develop a companion diagnostic assay that leverages our unique single EV biomarker discovery approach. Our technology focuses on intercepting the crosstalk between immune cells and tumor cells which aligns perfectly with YB-800’s unique therapeutic approach. Together, we can bring the next-generation diagnostic assay to cancer patients for more precise and reliable treatment guidance.”
